Likewise, the factor V Leiden (FVL) mutation confers resistance to activated protein C and has been associated with a > 3-fold higher odds of early-onset CTEPH in Europeans [6]. The gene discussed is PROC; the disease is chronic thromboembolic pulmonary hypertension.